Condition
Breast Cancer Invasive Nos
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Completed3
Terminated1
Unknown1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02005887Phase 2CompletedPrimary
TRial on the Endocrine Activity of Neoadjuvant Degarelix
NCT01598285TerminatedPrimary
A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer
NCT02794064Phase 1CompletedPrimary
A Prototype Tri-modal Imaging Device for Breast Cancer
NCT01630226Phase 2Unknown
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland
NCT00225927Not ApplicableCompletedPrimary
Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers
Showing all 5 trials